Montserrat Arnán

3.0k total citations
53 papers, 1.3k citations indexed

About

Montserrat Arnán is a scholar working on Hematology, Oncology and Epidemiology. According to data from OpenAlex, Montserrat Arnán has authored 53 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 18 papers in Oncology and 13 papers in Epidemiology. Recurrent topics in Montserrat Arnán's work include Acute Myeloid Leukemia Research (21 papers), Neutropenia and Cancer Infections (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Montserrat Arnán is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Neutropenia and Cancer Infections (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Montserrat Arnán collaborates with scholars based in Spain, United States and Italy. Montserrat Arnán's co-authors include Carlota Gudiol, Jordi Carratalà, Rafael F. Duarte, Carolina García‐Vidal, Isabel Sánchez‐Ortega, Josefina Ayats, Alberto Fernández de Sevilla, Beatriz Patiño, Carmen Ardanuy and Manuel Cuenca‐Estrella and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Montserrat Arnán

48 papers receiving 1.3k citations

Peers

Countries citing papers authored by Montserrat Arnán

Since Specialization

Citations

This map shows the geographic impact of Montserrat Arnán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Montserrat Arnán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Montserrat Arnán more than expected).

Fields of papers citing papers by Montserrat Arnán

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Montserrat Arnán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Montserrat Arnán. The network helps show where Montserrat Arnán may publish in the future.

Co-authorship network of co-authors of Montserrat Arnán

This figure shows the co-authorship network connecting the top 25 collaborators of Montserrat Arnán. A scholar is included among the top collaborators of Montserrat Arnán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Montserrat Arnán. Montserrat Arnán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases 2025 ·Diagnostic Pathology ·(unknown), (unknown), (unknown), Núria González, Francesca Guijarro, (unknown), Marta Pratcorona, Ignasi Gich, (unknown), Júlia Perera‐Bel, Lurdes Zamora, (unknown), Antònia Sampol, Antoni García‐Guiñón, Susana Vives, Mar Tormo, Montserrat Arnán, Neus Villamor, Josep Nomdedéu	0
2	Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial 2024 ·Clinical Microbiology and Infection ·Júlia Laporte-Amargós, Francisco Carmona-Torre, (unknown), Pedro Puerta‐Alcalde, Raül Rigo‐Bonnin, Marta Ulldemolins, Montserrat Arnán, José Luís del Pozo, Anna Torrent, Carolina García‐Vidal, Natàlia Pallarés, Cristian Tebé, Carmen Muñoz, Fé Tubau, Ariadna Padullés, Anna Sureda, Jordi Carratalà, Carlota Gudiol	1
3	Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study 2024 ·British Journal of Haematology ·Klaus Geißler, Zdeněk Kořı́stek, Teresa Bernal, Jan Novák, Gabriela Rodríguez‐Macías, Stephan Metzelder, Árpád Illés, Jiřı́ Mayer, Montserrat Arnán, Mary‐Margaret Keating, (unknown), Monia Lunghi, Nicola Stefano Fracchiolla, Uwe Platzbecker, Valeria Santini, Yuri Sano, Aram Oganesian, Harold Keer, Michael Lübbert	8
4	Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study 2024 ·Blood ·Pau Montesinos, Montserrat Arnán, Stéphane de Botton, María Calbacho, (unknown), Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, A. Harstrick, (unknown), (unknown), (unknown), Tania Witte, Eugene L. Saenger, Christian Récher	3
5	Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort 2023 ·Blood Cancer Journal ·(unknown), Marta Pratcorona, Ana Garrido, (unknown), Álex Bataller, Mar Tormo, Montserrat Arnán, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall‐Llovera, Antònia Sampol, (unknown), Marta Cervera, (unknown), Joan Bargay, Xavier Ortı́n, Josep Nomdedéu, Jordi Esteve, Jorge Sierra, (unknown)	9
6	Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8 2023 ·Cancers ·(unknown), (unknown), (unknown), Esperanza Such, Montserrat Arnán, Françesc Solé, Marina Díaz‐Beyá, María Díez‐Campelo, Mónica Del Rey, Teresa González, Jesús María Hernández‐Rivas	5
7	Characteristics and long‐term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic 2023 ·British Journal of Haematology ·(unknown), Helena Pomares, (unknown), Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), Mònica López‐Guerra, (unknown), (unknown), (unknown), Álex Bataller, Clara Maluquer, Dolors Colomer, Marı́a Rozman, Montserrat Arnán, Blanca Xicoy, Jordi Esteve, Marina Díaz‐Beyá	3
8	Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 2023 ·The Lancet Haematology ·Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, Mehmet Turgut, Ming‐Chung Wang, Roberto Cairoli, Hsin‐An Hou, Yok‐Lam Kwong, Montserrat Arnán, Stef Meers, Vinod Pullarkat, Valeria Santini, (unknown), (unknown), Julie Niolat, Pedro Marques Ramos, Hans D. Menssen, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker	36
9	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 2021 ·Blood Advances ·(unknown), Álex Bataller, Ana Garrido, Montserrat Hoyos, Montserrat Arnán, Susana Vives, Rosa Coll, Mar Tormo, Antònia Sampol, Lourdes Escoda, Olga Salamero, (unknown), Joan Bargay, (unknown), Josep Nomdedéu, Jordi Esteve, Jorge Sierra, Marta Pratcorona	19
10	Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies) 2020 ·Annals of Hematology ·Elena Bussaglia, Marta Pratcorona, (unknown), Laura San‐Segundo, Miguel A. Rubio, (unknown), (unknown), Isabel Badell, Jordi Esteve, Montserrat Arnán, Carme Talarn, Mar Tormo, (unknown), Ferran Vall‐Llovera, Xavier Ortı́n, Carme Pedro, Joan Bargay, Salut Brunet, Jorge Sierra, Josep Nomdedéu	5
11	Invasive fungal infections in AML / MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? 2016 ·Mycoses ·Helena Pomares, Montserrat Arnán, Isabel Sánchez‐Ortega, Anna Sureda, Rafael F. Duarte	36
12	Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease 2016 ·Croatian Medical Journal ·Isabel Sánchez‐Ortega, Rocío Parody, Octavio Servitje, Cristina Muniesa, Montserrat Arnán, Beatriz Patiño, Anna Sureda, Rafael F. Duarte	10
13	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes 2016 ·Modern Pathology ·Xavier Calvo, Leonor Arenillas, Elisa Luño, Leonor Senent, Montserrat Arnán, Fernando Ramos, María T. Ardañaz, Carme Pedro, Mar Tormo, María Julia Montoro, María Díez‐Campelo, Beatriz Arrizabalaga, Blanca Xicoy, Santiago Bonanad, Andrés Jerez, Benet Nomdedeu, Ana Ferrer, Guillermo Sanz, Lourdes Florensa	6
14	Immunodiagnostic Tests’ Predictive Values for Progression to Tuberculosis in Transplant Recipients 2015 ·Transplantation Direct ·Laura Muñoz, Aina Gomila‐Grange, Susana Boluda, José Castellote, Montserrat Arnán, Antoni Rafecas, Miguel Santín	13
15	Bloodstream infections in neutropenic patients with cancer: Differences between patients with haematological malignancies and solid tumours 2014 ·Journal of Infection ·Mar Marín, Carlota Gudiol, Carmen Ardanuy, Carolina García‐Vidal, Mariona Calvo, Montserrat Arnán, Jordi Carratalà	92
16	Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients 2014 ·Bone Marrow Transplantation ·Carlota Gudiol, Carolina García‐Vidal, Montserrat Arnán, Isabel Sánchez‐Ortega, Beatriz Patiño, Rafael F. Duarte, Jordi Carratalà	74
17	Serum Galactomannan-Based Early Detection of Invasive Aspergillosis in Hematology Patients Receiving Effective Antimold Prophylaxis 2014 ·Clinical Infectious Diseases ·Rafael F. Duarte, Isabel Sánchez‐Ortega, Isabel Cuesta, Montserrat Arnán, Belén Patiño, Alberto Fernández de Sevilla, Carlota Gudiol, Josefina Ayats, Manuel Cuenca‐Estrella	173
18	Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation 2013 ·Journal of Medical Economics ·Isabel Sánchez‐Ortega, Beatriz Patiño, (unknown), Montserrat Arnán, Teresa Peralta, (unknown), Alberto Fernández de Sevilla, Rafael F. Duarte	4
19	Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes 2013 ·PLoS ONE ·Carlota Gudiol, Josefina Ayats, Mariana Camoez, M.Á. Domínguez, Carolina García‐Vidal, Marta Bodro, Carmen Ardanuy, (unknown), Montserrat Arnán, Maite Antonio, Jordi Carratalà	51
20	Bacteraemia due to extended-spectrum -lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome 2009 ·Journal of Antimicrobial Chemotherapy ·Carlota Gudiol, L. Calatayud, Carolina García‐Vidal, Jaime Lora-Tamayo, M. Cisnal, Rafael F. Duarte, Montserrat Arnán, (unknown), Jordi Carratalà, F. Gudiol	138

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact